Real-time monitoring of daunorubicin pharmacokinetics with nanoporous electrochemical aptamer-based sensors in vivo

The metabolic differences between patients with the anticancer drug daunorubicin (DRN) pose difficulties in providing clinical delivery strategies for different patients. Therefore, it is urgent to develop a pharmacokinetic platform that can real-time monitor drug levels in vivo to achieve precise drug delivery and reduce drug side effects. To this end, an electrochemical aptamer-based (E-AB) sensor was designed to realize real-time and continuous monitoring of DRN levels in vivo and obtain DRN pharmacokinetics of different individuals for the first. Specifically, the binding free energy of the aptamer to the target was calculated by molecular docking simulations. Using nanoporous gold working electrodes with immobilized aptamers as E-AB sensors, which monitored DRN in the blood of different rat models continuously for many hours with nanomolar precision and second resolution, and hundreds of DRN concentration values were obtained, based on which important pharmacokinetic parameters were simulated and computed, including half-life of drug DRN distribution and elimination, and peak concentration in blood. These parameters help to determine the metabolism of drug DRN in different patients and adjust the administered dose in time to achieve precise treatment. Therefore, this E-AB platform may provide a valuable new tool for clinicians to monitor pharmacokinetics in different patients.